# Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Source: https://onco.cc/trials/nct00563836/  
OnCo record `nct00563836` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Catumaxomab in Ovarian cancer, run by Neovii Biotech, completed.

## Summary

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer is a phase 2 interventional study registered as NCT00563836 by Neovii Biotech, with 41 participants recorded, started 2007-11 and reaching its primary completion in 2008-09. Interventions recorded: Catumaxomab. Conditions recorded: Ovarian Cancer, Epithelial Ovarian Cancer.

Linked to the drug Catumaxomab because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00563836
- Phase: 2
- Setting: Multicenter, Single-arm, Phase II Study of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intra- and Postoperatively in Patients With Epithelial Ovarian Cancer
- Sponsor: Neovii Biotech
- Enrolled: 41

## Sources

- ClinicalTrials.gov NCT00563836: https://clinicaltrials.gov/study/NCT00563836

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Catumaxomab](https://onco.cc/drugs/catumaxomab/)
- companies: [Neovii](https://onco.cc/companies/neovii/)

---
JSON: https://onco.cc/api/v1/entities/nct00563836.json